All Type of News
Aronamin’s significant growth expected to hit KRW 50 billion annual sales
It seems the Ildong Pharmaceutical’s most well-known OTC drug, Aronamin, will exceed the KRW 50 billion annual sales.
The drug has attracted outstanding interests as becoming the first vitamin supplement which might ...
Will details about lecture and consultant fees be included in exception clause?
When it comes to ‘lecture and consultant fees,’ positive atmosphere has been sensed. The issue was limitation of the pharmaceutical industry which have no choice but to depend on voluntary restriction for lecture and ...
Stagnation of domestic growth hormone products
The growth hormone market, which has kept its growth every year, hit stagnation from this year. Particularly, as domestic companies which has occupied the market have been slow, market shares of imported pharmaceutica...
Health insurance benefit of severe COPD drugs expanded
The health insurance benefit standard of ‘Daxas,’ an oral COPD treatment, is anticipated to be expanded.
According to the industry concerned on the 14th, the Health Insurance Review & Assessment Service(HIRA) is curr...
“Multinational companies’ clinical studies bring KRW 52 billion domestic medical expense reduction effect”
It was researched multinational clinical studies which have been conducted by global pharmaceutical companies has made medical expense reduction worth of, at least, KRW 52 billion in the domestic market.
According to...
Possibility to expand obesity treatment benefit
While obesity has become a social issue, the Ministry of Health and Welfare(MOHW) attracted attention as expressing a positive opinion on the health insurance benefit expansion of obesity treatments.
Director Sung-wo...
Clear decreasing trend of medical institutions’ drug prescription rates
It was known injection and antibiotics prescription rates were continuously decreasing after the result of the health insurance benefit deliberation of medical institutions were unveiled.
According to the 2014 Annual...
Only 5 blockbusters among 26 domestically developed new drugs
Among domestically developed new drugs which were launched after 1999, there are only 5 blockbuster-level pharmaceutical products exceeding KRW 10 billion annual actual outputs, but the Boryung Pharm’s hypertension tr...
KRW 42.8 trillion in last year’s health insurance claims
In 2014, the national health insurance benefit claims were increased by 7.9% to KRW 42.8275 trillion, and the national insurance medical expenses were increased by 6.8% to KRW 54.4272 trillion.
According to the...
Abbott Korea launches film-type hepatitis B treatment for the first timeToday, Abbott Korea(CEO Yoo-seok Jung) launched ‘Filclude ODF(generic name: entecavir),’ the first film-type hepatitis B treatment, in respective 0.5mg and 1mg.
‘Filclude ODF,’...
|
